Phase 2Recruiting
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
- Sponsor
- UConn Health (Academic or other)
- Enrolment
- 60 planned
- Conditions
- Frailty; Mild Cognitive Impairment; Aging
- Interventions
- Mitoquinone Mesylate; Placebo capsule
- Ages
- older adults
- Registry
- NCT06027554
From the registry
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Primary outcomes
- Change in Vascular Endothelial Function
- Change in Cerebrovascular Function
- Change in NIH Tool Box Composite
- Change in walking speed